Study identifier:4522AT/0001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open-label, randomised, multi-centre, phase IIIb, parallel group study to compare the efficacy and safety of 10mg and 40mg rosuvastatin (CRESTOR)
hypercholesterolaemia
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|